Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term follow-up study of bilateral AAV5-hRKp.RPGR gene therapy for X-linked retinitis pigmentosa
MOH_2022-03-28_009700Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2021
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label trial of botaretigene sparoparvovec in X-linked retinitis pigmentosa (XLRP) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Not specified. Started Apr 2021; status: recruiting.
02
Drugs
botaretigene sparoparvovec
03
Conditions
X-linked retinitis pigmentosa (XLRP)
Beyond the preview
Go deeper on MOH_2022-03-28_009700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-28_009700.